KMTS
Kestra Medical Technologies, Ltd.27.00
+0.52+1.96%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
Market accelerates; share grabs lead.
Q&A spotlighted WCD market growth hitting low-to-mid teens, up from 11% last quarter, driven by Kestra's sales expansion, rival studies highlighting risks, and the incumbent chasing volume amid share losses. Prescriptions surged sequentially from 70-75% installed-base gains and 25% new prescribers, with no drag from Zoll's slow-rolling larger device or pricing. Florida Medicaid wins and VA access unlock gradual share and margin tailwinds; new reps ramp crisply. Conversion rose YoY to 46% despite H2 deductibles. Share gains dominate—for now. Confident tone persists; watch guidelines for market explosion.
Key Stats
Market Cap
1.58BP/E (TTM)
-Basic EPS (TTM)
-3.96Dividend Yield
0%Recent Filings
8-K
Q3 revenue surges 63%
Kestra Medical Technologies crushed Q3 FY26 with $24.6M revenue, up 63% year-over-year, fueled by 58% more ASSURE system prescriptions and WCD market gains. Gross margin jumped to 52.6% from 43.4% via volume leverage and in-network shifts, yet net loss widened to $34.2M on commercial ramp-up. Revenue guidance hiked to $93M for FY26. Cash swelled to $291M post-equity offering.
10-Q
Q3 FY2026 results
Kestra Medical Technologies ramped revenue 63% y/y to $24.6M in Q3 FY2026 ended January 31, 2026, with gross profit doubling to $12.9M as cost efficiencies from longer equipment lives cut depreciation. Yet SG&A surged 79% y/y to $42.7M on headcount growth and $10.1M stock-based comp, driving operating loss wider to $34.8M and diluted EPS to -$0.61 (55.8M shares, reconciles). Cash swelled to $291.3M post-$149M equity offering, funding $63M YTD operating burn; $45M Term Loan (due 2028, SOFR+7.25%) in covenant compliance. Revenue hinges on patient adoption.
8-K
Q2 revenue up 53%
Kestra Medical Technologies posted Q2 FY26 revenue of $22.6 million, up 53% year-over-year, with gross margin surging to 50.6% from 39.6% on volume leverage and in-network patient mix. Prescriptions for its ASSURE system jumped 54% to 4,696. It raised FY26 revenue guidance to $91 million. Cash hit $175 million, excluding $148 million from a December equity offering.
10-Q
Q1 FY2026 results
Kestra Medical Technologies ramped revenue 53% y/y to $22.6M in Q1 FY2026 ended October 31, 2025, with gross profit doubling to $11.4M as costs per patient fell 20% from better rental pool use and volume efficiencies. Yet SG&A ballooned 79% y/y to $38.3M on public company costs and headcount for sales growth, driving operating loss to $31.8M and diluted EPS to -$0.64 on 51.4M shares—reconciles precisely, no anti-dilution. Cash burned $44.6M in ops (FCF not disclosed in the 10-Q) yet ended at $175.4M with $41.9M net debt (Term Loan 2024 at SOFR+7.25%, due 2028, covenants met); follow-on offering added $149.2M net post-quarter. Revenue hinges on reimbursement from payors like Medicare.
8-K
IPO closes, $148M raised
Kestra Medical Technologies closed its public offering of 6.9 million common shares at $23.00 each on December 4, 2025, raising ~$148.4 million in net proceeds. Funds will fuel sales, marketing, commercialization, R&D, clinical studies, and general corporate needs. Underwriting agreement includes standard protections.
IPO
Website
Employees
Sector
Industry
BEAT
Heartbeam, Inc.
3.44+0.81
HSCS
HeartSciences Inc.
2.31-0.16
HSDT
Solana Company
3.10+0.06
IRTC
iRhythm Technologies, Inc.
167.90-1.10
KRMD
KORU Medical Systems, Inc.
5.77-0.04
MDT
Medtronic plc.
97.72-0.85
NMTC
NeuroOne Medical Technologies C
0.71+0.05
RMD
ResMed Inc.
247.34-5.73
VTAK
Catheter Precision, Inc.
2.19-0.04
WOK
WORK Medical Technology Group L
0.05-0.01